References:

1.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.

2.

Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci. 2004;1028:150-156.

3.

Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517.

4.

Rastogi RP, Sinha R, Sinha RP. Apoptosis: molecular mechanisms and pathogenicity. EXCLI J. 2009;8:155-181.

5.

Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630.

6.

Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med. 2000;192:F21-F25.

7.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.

8.

Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.

9.

Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.

10.

Lane D. p53 from pathway to therapy. Carcinogenesis. 2004;25:1077-1081.

11.

Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143-2159.

12.

Jumaa H, Hendriks RW, Reth M. B-cell signaling and tumorigenesis. Ann Rev Immunol. 2005;23:415-445.

13.

Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23:9408-9421.

14.

Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364-6369.